IGM Biosciences, Inc. financial data

Symbol
IGMS on Nasdaq
Industry
Pharmaceutical Preparations
Location
325 E Middlefield Road, Mountain View, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Palingen, Inc. (to 7/16/2010)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 865 % -20.1%
Debt-to-equity 100 % +41.7%
Return On Equity -108 % -45.5%
Return On Assets -54 % -24%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 132 M USD -39.7%
Weighted Average Number of Shares Outstanding, Basic 60.1 M shares +35.2%
Weighted Average Number of Shares Outstanding, Diluted 60.1 M shares +35.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 208 M USD +8.96%
General and Administrative Expense 47.6 M USD -4.13%
Operating Income (Loss) -254 M USD -6.09%
Nonoperating Income (Expense) 17.6 M USD +60.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -236 M USD -3.46%
Income Tax Expense (Benefit) 591 K USD +579%
Net Income (Loss) Attributable to Parent -237 M USD -3.68%
Earnings Per Share, Basic -4.21 USD/shares +17.8%
Earnings Per Share, Diluted -4.21 USD/shares +17.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 79.2 M USD -43.5%
Marketable Securities, Current 236 M USD -19.1%
Assets, Current 303 M USD -21.3%
Property, Plant and Equipment, Net 37.3 M USD +1.55%
Operating Lease, Right-of-Use Asset 34.5 M USD -11.8%
Other Assets, Noncurrent 1.61 M USD -25.6%
Assets 376 M USD -18.7%
Accounts Payable, Current 4 M USD +0.58%
Accrued Liabilities, Current 23.7 M USD -20.2%
Liabilities, Current 37.9 M USD -13.1%
Operating Lease, Liability, Noncurrent 34.3 M USD -1.63%
Liabilities 215 M USD -3.78%
Accumulated Other Comprehensive Income (Loss), Net of Tax -128 K USD +63.1%
Retained Earnings (Accumulated Deficit) -871 M USD -37.4%
Stockholders' Equity Attributable to Parent 161 M USD -32.7%
Liabilities and Equity 376 M USD -18.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42.4 M USD +16.8%
Net Cash Provided by (Used in) Financing Activities 152 K USD +103%
Net Cash Provided by (Used in) Investing Activities 8.65 M USD -87.6%
Common Stock, Shares Authorized 120 M shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -33.6 M USD -278%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 79.5 M USD -43.5%
Deferred Tax Assets, Valuation Allowance 267 M USD +41.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 280 M USD +39.4%
Operating Lease, Liability 40.5 M USD -1.62%
Depreciation 2.18 M USD +30.8%
Payments to Acquire Property, Plant, and Equipment 2.48 M USD -36.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -237 M USD -3.51%
Lessee, Operating Lease, Liability, to be Paid 55.2 M USD -10.4%
Property, Plant and Equipment, Gross 58.8 M USD +28.4%
Operating Lease, Liability, Current 6.63 M USD +3.14%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.1 M USD -17.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.89 M USD +14.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.3 M USD -18.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.21 M USD +1.72%
Deferred Tax Assets, Operating Loss Carryforwards 73.4 M USD -8.78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200 M shares 0%
Unrecognized Tax Benefits 10.6 M USD +52.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.38 M USD +2.74%
Operating Lease, Payments 8.1 M USD +46%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%